|
5.6 ESMO
|
|
|
Financial Difficulties Linked to Worse Outcomes From Cancer Treatment [ESMO]
|
|
|
|
|
|
Researchers
pooled data from 16 prospective multicenter trials in Italy involving a
total of 3670 patients with either lung, breast or ovarian cancer,
which included the EORTC quality of life C30 questionnaire. Question 28
of this questionnaire asks patients to rate financial difficulties
related to their disease or treatment on a scale from ‘not at all’ to
‘very much’.
|
|
|
|
|
|
|
First Feasibility Study of the ESMO-MCBS Scale in Rare Tumour Entities [ESMO]
|
|
|
|
|
|
The
ESMO-MCBS is a new tool to quantify the clinical benefit of a certain
drug for the treatment of cancer and its application in daily clinical
practice. It was first evaluated on common tumour entities by one of
Europe’s largest cancer centres, the Medical University of Vienna (MUV),
which also conducted this new study.
|
|
|
|
|
|
|
5.6.1 ESMO - Essais
|
|
|
Single-Arm Trials Improve Early Access to Rare Cancer Drugs [ESMO]
|
|
|
|
|
|
Dr
Lacombe concluded: “Clinical researchers must develop new solutions
that span from proof of concept to effectiveness, constantly taking the
challenges to bring solid evidence to patients and not too easily
compromising towards easier routes such as SATs which should be limited
to situations where strong biological evidence emerges in absence of
relevant existing therapeutic strategies and/or unmet needs. Discussing
SATs outside of a complete transformation of clinical research may
jeopardise appropriate recognition of SATs where they may be useful and
is certainly a disservice to patients.”
|
|
|
|
|
|
|
5.6.10 ESMO - Vessie
|
|
|
|
|
|
|
5.6.11 ESMO- Rein
|
|
|
|
|
|
5.6.12 ESMO - Observation
|
|
|
|
True Burden of Head and Neck Cancer in France Underestimated by More Than One-Third [ESMO]
|
|
|
|
|
|
The
EPICORL researchers also found that the national cause of death
statistics underestimated the burden of head and neck cancer by 38%.2
Investigator Dr Caroline Even, from the department of Head and Neck
Cancer at Gustave Roussy said this was likely due to the fact that 43%
of the 41,503 patients who died in hospital with advanced head and neck
cancer were also treated for a cancer other than head and neck.
|
|
|
|
|
|
|
|
|
5.6.13 ESMO - Prostate
|
|
|
Custirsen Shows no Survival Benefits in Metastatic Prostate Cancer [ESMO]
|
|
|
|
|
|
“Despite
the negative outcome of the trial, the evaluation of custirsen in
prostate cancer was conducted on the basis of solid preclinical and
clinical evidence supporting anti-tumour activity,” said principal
investigator Professor Karim Fizazi, head of the Department of Cancer
Medicine at the Institut Gustave Roussy, Villejuif, France.
|
|
|
|
|
|
|
|
5.6.14 ESMO - Ovaire
|
|
|
|
|
The race to create a new class of ovarian cancer drugs heats up [STAT]
|
|
|
|
|
|
Ovarian
cancer has historically been one of the harder cancers to treat — but a
promising new class of drugs, called PARP inhibitors, is proving
powerful in delaying the growth of tumors by preventing cancer cells
from repairing themselves after they’ve been damaged by chemotherapy.
|
|
|
|
|
|
|
|
|
Tesaro makes its case for a clean sweep with niraparib, voiding need for a diagnostic [EndPoints]
|
|
|
|
|
|
We
already knew going into the big ESMO meeting that Tesaro’s PARP
inhibitor niraparib had demonstrated stellar results for a range of
ovarian cancer patients with BRCA mutations. But when investigators
stood up to display the results of their pivotal study, a full set of
data demonstrated a benefit not only for tumors that were positive for
HRD, an important biomarker, but also for HRD-negative tumors.
|
|
|
|
|
|
|
|
|
5.6.15 ESMO - VADS
|
|
|
|
|
Immunotherapy cancer drug hailed as 'game changer' [BBC News]
|
|
|
|
|
|
In
a study of head and neck cancer, more patients taking nivolumab
survived for longer compared with those who were treated with
chemotherapy. In another study, combining nivolumab with another drug
shrank tumours in advanced kidney cancer patients.
|
|
|
|
|
|
|
|
5.6.2 ESMO - Divers
|
|
|
|
|
|
|
|
5.6.4 ESMO - Poumon
|
|
|
|
|
|
MEK Inhibition in KRAS-mutant NSCLC Did Not Improve Survival [ESMO]
|
|
|
|
|
|
At
data cut-off, median progression-free survival was not significantly
different between the selumetinib arm and placebo arm (3.9 months vs.
2.8 months, HR 0.93, p=0.44), nor was there a significant difference in
median overall survival (8.7 months vs. 7.9 months, HR 1.05, p=0.64).
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
5.6.5 ESMO - Mélanome & Peau
|
|
|
|
|
|
|
5.6.6 ESMO - Sein
|
|
|
|
|
|
|
|
|
Encouraging Results For Ribociclib In Advanced Breast Cancer [Forbes]
|
|
|
|
|
|
My
first question about Novartis’s new medication, ribociclib, is how it
compares with palbociclib (Ibrance). Unfortunately, because these drugs
have been evaluated in separate clinical trials, sponsored by
independent pharmaceutical companies, by oncologists at distinct sets of
medical centers, it’s hard to discern the differences.
|
|
|
|
|
|
|
|
5.6.8 ESMO - Côlon-rectum
|
|
|
|
|
|
|
|
|